United States

Adam Lohr

Partner, Life Sciences Senior Analyst

Areas of focus: Life Sciences


In January 2019, Adam was selected as a senior analyst in RSM’s cutting-edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions influencing middle market leaders. Adam’s focus is on the life sciences industry.  

Summary of experience

Adam has more than 10 years of accounting and finance experience, serving private equity backed and private closely-held companies in the middle market. He focuses on high-growth companies that are globally active in the technology, SaaS and consumer products industries. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their businesses.

Prior to joining RSM, Adam was a manager of assurance and risk advisory services. In addition to leading financial statement audits, he performed fraud investigations, business process analysis, and the development of effective oversight and governance environments. 

Adam is an instructor at the regional and national level, and is well-versed in the application of ASC 606 revenue recognition for the technology and consumer products industries. 

Professional Affiliations and Credentials

  • Certified Public Accountant
  • Certified Fraud Examiner
  • American Institute of Certified Public Accountants


  • Bachelor of Science, business administration, University of Arizona
  • Masters of Accountancy, University of Arizona

Recent Perspectives


3D printing's use in life sciences is more than masks and ventilators

Surging demand for personal protective equipment has lead to a renewed focus on the potential for 3D printing in the life sciences industry.

Cyberattacks threaten companies researching COVID-19 vaccine


Cyberattacks threaten companies researching COVID-19 vaccine

More promise, more problems: Cyberattacks threaten life sciences companies researching COVID-19 vaccine.

Life sciences industry outlook


Life sciences industry outlook

Amid the COVID-19 pandemic, life sciences companies, thrust in the spotlight, are positioned for strong growth.


Strategies for life sciences companies expanding to U.S.

Learn about opportunities for life sciences foreign direct investment (FDI) into the United States with this complimentary webcast.


Life sciences finance leaders discuss strategies to scale businesses

From contract research organizations to initial public offerings, life sciences finance leaders discuss issues in the bioscience businesses.


Life sciences by the numbers: IPOs, deals, M&A and more

RSM senior industry analyst Adam Lohr shares the latest on deals, going public and more in the biotech, pharma and medical devices sectors.


To discuss how our team can help your business, contact us by phone 800-274-3978.


+1 619 641 7343
Connect on Linkedin